NEW YORK, NY / ACCESSWIRE / February 23, 2017 / The Pawar Law Group announces a class action lawsuit on behalf of Novo Nordisk A/S. (“Novo Nordisk” or the “Company”) (NVO) investors who purchased Novo Nordisk between April 30, 2015 and October 27, 2016, inclusive (the “Class Period”). The suit is for recovery of investor losses.

To participate in this class action lawsuit, visit the firm’s website at http://pawarlawgroup.com/cases/novo-nordisk/ or email Vik Pawar, Esq. at [email protected] or call toll free at (866) 999-0873.

No class has been certified in the above action yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the lawsuit, throughout the Class Period Novo Nordisk reported materially false and misleading earnings and forecasts in that they were inflated through the collusive price fixing of Novo Nordisk’s insulin drugs. The lawsuit also alleges that Novo Nordisk misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you wish to serve as lead plaintiff, you must move the Court no later than March 13, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You may join the case here: http://pawarlawgroup.com/cases/novo-nordisk/ or email Vik Pawar, Esq. at [email protected]

Contact:

Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1210
New York, NY 10007
Tel: (212) 571-0805
Fax: (212) 571-0938
[email protected]

For more information, please visit the source link below.